840529-13-7
Chemical Structure
Helioxanthin 8-1
Synonym(s): Helioxanthin analogue 8-1
- CAS. Nr.: 840529-13-7
- Formula:C20H12N2O6
- Molecular Weight:376.32
IUPAC Name: 11-(benzo[d][1,3]dioxol-5-yl)-8,9-dihydro-[1,3]dioxolo[4',5':3,4]benzo[1,2-g]phthalazine-7,10-dione
InChIKey: PXSPEYYAEFFUMN-UHFFFAOYSA-N
SMILES: O=C1NNC(C2=C(C3=CC=C(OCO4)C4=C3)C5=C6C(OCO6)=CC=C5C=C21)=O
Biological Activity: Helioxanthin 8-1(Helioxanthin analogue 8-1) is an anti-HBV agent. Helioxanthin 8-1 exhibits anti-hepatitis B virus activity in both in vitro human hepatitis B virus models and animal models. Helioxanthin 8-1 inhibits the synthesis of duck hepatitis B virus (DHBV) DNA, covalently closed circular DNA, RNA and proteins, thereby blocking DHBV replication. Helioxanthin 8-1 shows higher cytotoxicity in virus-induced cells than in non-induced cells. Helioxanthin 8-1 can be used in studies related to hepatitis B virus infection[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Helioxanthin 8-1 | 98.0% | Helioxanthin 8-1(Helioxanthin analogue 8-1) is an anti-HBV agent. Helioxanthin 8-1 exhibits anti-hepatitis B virus activity in both in vitro human hepatitis B virus models and animal models. Helioxanthin 8-1 inhibits the synthesis of duck hepatitis B virus (DHBV) DNA, covalently closed circular DNA, RNA and proteins, thereby blocking DHBV replication. Helioxanthin 8-1 shows higher cytotoxicity in virus-induced cells than in non-induced cells. Helioxanthin 8-1 can be used in studies related to hepatitis B virus infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ying C, et al. Helioxanthin analogue 8-1 inhibits duck hepatitis B virus replication in cell culture. Antivir Chem Chemother. 2010;21(2):97-103. [Content Brief]
- [2]. Stefanik M, et al. Antiviral Activity of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2. Microorganisms. 2021;9(3):471. Published 2021 Feb 25. [Content Brief]
Keywords
